IGF-1 LR3 and Metformin Interaction
IGF-1 LR3 and Metformin have an interaction requiring monitoring for interaction with 90% confidence. May mitigate insulin resistance. These compounds primarily affect different organ systems.
Compound Profiles
IGF-1 LR3
Modified Growth Factor Analog | Muscle Growth
Functions as a full IGF-1 receptor agonist activating PI3K/Akt/mTOR and MAPK/ERK pathways. The modifications prevent protein sequestration, maintaining elevated free circulating levels for extended anabolic effects.
View full profileMetformin
Biguanide | AMPK Activator & Longevity Research
Metformin exerts its primary effects through activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. AMPK activation triggers a cascade of downstream metabolic improvements: enhanced glucose uptake in skeletal muscle, suppression of hepatic gluconeogenesis, improved mitochondrial function, and increased fatty acid oxidation.
View full profileCombined Organ Load
Frequently Asked Questions
Can I take IGF-1 LR3 with Metformin?
Yes, but with caution. May mitigate insulin resistance. Regular monitoring is advised.
Is IGF-1 LR3 and Metformin safe together?
Based on documented research, this combination is considered monitor. No critical safety flags identified for this pair.
What are the interactions between IGF-1 LR3 and Metformin?
May mitigate insulin resistance. This assessment has 90% confidence and is based on documented research data.
How should I time IGF-1 LR3 and Metformin?
IGF-1 LR3 has a half-life of 20-30 hours and Metformin has a half-life of ~5 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.